The "Orphan Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

This report analyzes the worldwide markets for Orphan Drugs in US$ Million by the following Product Segments:

  • Biologics
  • Non-Biologics

The report profiles 140 companies including many key and niche players such as:

  • AbbVie, Inc. (USA)
  • Actelion Pharmaceuticals Ltd. (Switzerland)
  • Alexion Pharmaceuticals, Inc. (USA)
  • Amgen, Inc. (USA)
  • AstraZeneca Plc. (UK)
  • Bayer AG (Germany)
  • Biogen Inc. (USA)
  • BioMarin Pharmaceutical Inc. (USA)
  • Boehringer Ingelheim GmbH (Germany)
  • Bristol-Myers Squibb Company (USA)
  • Celgene Corp. (USA)
  • CEL-SCI Corporation (USA)
  • Concordia International Corp. (Canada)
  • Eli Lilly and Company (USA)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Johnson & Johnson (USA)
  • Merck & Co., Inc. (USA)
  • Merck Serono International S.A. (Germany)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (USA)
  • Recordati S.p.A. (Italy)
  • Orphan Europe (France)
  • Shire Plc. (Ireland)
  • Sanofi SA (France)
  • Genzyme Corp. (USA)
  • Vertex Pharmaceuticals (USA)

Key Topics Covered:

1. Industry Overview

2. Growth Drivers

3. Select Market Trends

4. Orphan Drug Fda Approvals

5. Orphan Drug Designations

6. Regulatory Scenario

7. Product Overview

8. Select Product Approvals/Launches

9. Recent Industry Activity

10. Focus On Select Players

11. Global Market Perspective

Total Companies Profiled: 140 (including Divisions

Subsidiaries (151)

  • The United States (77)
  • Canada (8)
  • Japan (8)
  • Europe (51)
    • France (10)
    • Germany (4)
    • The United Kingdom (7)
    • Italy (3)
    • Rest of Europe (27)
  • Asia-Pacific (Excluding Japan) (3)
  • Middle East (4)

For more information about this report visit https://www.researchandmarkets.com/research/s7xnlh/orphan_drugs?w=4